Position in CHRS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$67
+$10 QoQ
Shares Held
40
-49.4% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2023
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in CHRS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Larson Financial Group LLC holds $5,564,070 across 194 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,302 | $646,742 | |
| 2 | INCY |
Incyte Corp
|
4,050 | $459,108 | |
| 3 | TGTX |
Tg Therapeutics, Inc.
|
7,292 | $400,622 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
627 | $390,959 | |
| 5 | EXEL |
Exelixis, Inc.
|
4,507 | $245,225 | |
| 6 | IONS |
Ionis Pharmaceuticals Inc
|
3,000 | $237,870 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
613 | $184,531 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
709 | $170,847 |
All Filings in CHRS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $67 | 40 | Shares | Sole | 2026-05-15 | |
| 2025-06-30 | $57 | 79 | Shares | Sole | 2025-08-08 | |
| 2024-12-31 | $202 | 147 | Shares | Sole | 2025-02-07 | |
| 2024-09-30 | $152 | 147 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $123,677 | 71,490 | Shares | Sole | 2024-08-02 | |
| 2024-03-31 | $176,766 | 73,961 | Shares | Sole | 2024-05-03 | |
| 2023-12-31 | $489 | 147 | Shares | Sole | 2024-02-01 | |
| 2023-09-30 | $549 | 147 | Shares | Sole | 2023-11-03 | |
| 2023-03-31 | $187,477 | 27,409 | Shares | Sole | 2023-05-04 | |
| No filing history on record for this holder in this stock. | ||||||